首页> 美国卫生研究院文献>International Journal of Clinical and Experimental Medicine >Different regulation of Toll-like receptor 4 expression on blood CD14+ monocytes by simvastatin in patients with sepsis and severe sepsis
【2h】

Different regulation of Toll-like receptor 4 expression on blood CD14+ monocytes by simvastatin in patients with sepsis and severe sepsis

机译:辛伐他汀对败血症和严重脓毒症患者血液中CD14 +单核细胞Toll样受体4表达的不同调节

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We have demonstrated that regulation of Toll-like receptor 4 (TLR4) surface expression levels on blood CD14+ monocytes by simvastatin treatment in patient with sepsis is different from that in patients with severe sepsis. In patients with sepsis simvastatin treatment statistically significantly decreased TLR4 surface expression level on blood CD14+ monocytes, while in patients with severe sepsis simvastatin treatment had no significant influence on TLR4 surface expression level on blood CD14+ monocytes. The changes of plasma interleukin-6 (IL-6) induced by simvastatin in patients with sepsis and severe sepsis were similar with that of TLR4. Our results indicated simvastatin treatment differently influenced inflammation process in patients with sepsis and severe sepsis, which might partially explain the discrepancy, presented by previous trials, about the therapeutic effects of simvastatin treatment in patients with sepsis and severe sepsis.
机译:我们已经证明,辛伐他汀治疗脓毒症患者对血液CD14 + 单核细胞的Toll样受体4(TLR4)表面表达水平的调节与严重脓毒症患者不同。脓毒症辛伐他汀治疗的患者血液中CD14 + 单核细胞的TLR4表面表达水平显着降低,而严重脓毒症辛伐他汀治疗的患者血液CD14 +对TLR4表面表达水平无明显影响单核细胞。辛伐他汀引起的脓毒症和严重脓毒症患者血浆白细胞介素-6(IL-6)的变化与TLR4相似。我们的结果表明辛伐他汀治疗对脓毒症和严重脓毒症患者的炎症过程有不同的影响,这可能部分解释了先前试验中关于辛伐他汀治疗脓毒症和严重脓毒症的疗效差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号